Jim Cramer Recommends GW Pharmaceuticals Pot Stock as Epidiolex Proves Beneficial


The London-based GW Pharmaceuticals, which produces CBD-enriched products like Sativex and Epidiolex, announced that the latter of its two products (Epidiolex) has “produced promising results in children and young adults with treatment-resistant epilepsy.” The company prescribed and monitored the performance of Epidiolex on 27 individuals over a 12-week span.

According to The Street, “The drug showed at least a 50% reduction in seizures for 48% of the patients, with 15% of patients reportedly being seizure-free.” For both GW Pharmaceuticals and patients poised to benefit from CBD-rich products, this result shines as a major win and a potential boon for health care and this company’s pot stock fortune.

Buoyed by a Jim Cramer (the CNBC stock advisor) endorsement, GW Pharmaceuticals stock (traded as GWPH) has begun to skyrocket. Cramer offered this brief but telling sentence of support for GWPH on his “Cramer’s Stop Trading” segment.

“I think this is becoming a non-speculative stock.”

In layman terms, Carmer believes GW Pharmaceuticals and its products are the real deal. If and when the FDA approves Epidiolex for use both overseas and in America, one would expect this stock to keep climbing.


About Author

Barry has been writing about marijuana for over five years. Prior to joining Marijuana.com, Barry wrote about sports and music. His work has appeared on TIME, The Huffington Post, Deadspin, and elsewhere on the Internet. In his spare time, he enjoys disco and Kosher Kush.

1 Comment

Leave A Reply